<DOC>
	<DOCNO>NCT00934375</DOCNO>
	<brief_summary>This multi-center , open-label study 28 week duration subject Mild Cognitive Impairment complete double-blind study ( E2020-A001-412 ) .</brief_summary>
	<brief_title>A 28-Week Open Label Extension Study Evaluating Safety Tolerability Donepezil Hydrochloride Subjects With Mild Cognitive Impairment</brief_title>
	<detailed_description />
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Age Range : Adult subject ( 45 90 year age inclusive ) 2 . Sex distribution : Men woman . Women childbearing potential ( &lt; 1 year post menopausal ) must practice effective contraception negative serum BHCG Screening . [ Women breastfeeding exclude . ] 3 . Subjects must complete one year , doubleblind core trial ( E2020A001412 ) . 4 . A complete Diagnostic Worksheet end doubleblind core trial ( E2020A001412 ) indicate conversion Alzheimer 's Disease dementia . 5 . Health : Generally healthy ambulatory ambulatoryaided ( i.e. , walker cane ) . 6 . The subject must expect complete entire study . 7 . Subjects must sufficiently fluent English . 8 . Subjects must informant daily contact subject ( e.g. , average 10 hour per week ) , observe possible adverse event accompany subject visit . 9 . Clinical laboratory value must within normal limit , abnormal , judge clinically insignificant investigator ( likely cause cognitive impairment medical instability ) . 1 . Subjects complete terminate early one year , doubleblind core trial ( E2020A001412 ) . 2 . Any subject without complete diagnostic worksheet Week 51 core doubleblind trial ( E2020A001412 ) . 3 . Any subject complete diagnostic worksheet Week 51 core doubleblind trial ( E2020A001412 ) indicate conversion Alzheimer 's dementia . 4 . Subjects uncontrolled hypertension ( sit systolic &gt; = 160mmHg and/or diastolic &gt; =95mmHg ) assess investigator , regardless whether subject take antihypertensive medication . 5 . Subjects history malignant neoplasm treat within five year prior study entry ( basal squamous cell carcinoma skin ) ; current evidence malignant neoplasm ; recurrent matastatic disease . 6 . Subjects suffer severe infection major surgical procedure within three month prior baseline . 7 . Subjects may able comply protocol . 8 . Subjects know hypersensitivity piperidine derivative acetylcholinesterase ( AChE ) inhibitor . 9 . Subjects diabetes mellitis control diet and/or medication random serum glucose value &gt; 170mg/dl . 10 . Any condition would make subject , opinion investigator , unsuitable study . 11 . Subjects reliable informant ( e.g. , informant contact subject le 10 hour per week ) .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Mild Cognitive Impairment</keyword>
</DOC>